KMT2C and cancer: On the other hand, it was also shown that BAF (SMARCA4 and SS18) does not require pre-marked H3K4me1 for binding and that targeting of ectopic SMARCA4 in SMARCA4-deficient cancer cells establishes MLL3/4 genomic binding and active enhancer marks de novo42.